1. Ubiquitin C-Terminal Hydrolase-L1 Potentiates Cancer Chemosensitivity by Stabilizing NOXA
- Author
-
Kerstin Brinkmann, Paola Zigrino, Axel Witt, Michael Schell, Leena Ackermann, Pia Broxtermann, Stephan Schüll, Maria Andree, Oliver Coutelle, Benjamin Yazdanpanah, Jens Michael Seeger, Daniela Klubertz, Uta Drebber, Ulrich T. Hacker, Martin Krönke, Cornelia Mauch, Thorsten Hoppe, and Hamid Kashkar
- Subjects
Biology (General) ,QH301-705.5 - Abstract
The BH3-only protein NOXA represents one of the critical mediators of DNA-damage-induced cell death. In particular, its involvement in cellular responses to cancer chemotherapy is increasingly evident. Here, we identify a strategy of cancer cells to escape genotoxic chemotherapy by increasing proteasomal degradation of NOXA. We show that the deubiquitylating enzyme UCH-L1 is a key regulator of NOXA turnover, which protects NOXA from proteasomal degradation by removing Lys48-linked polyubiquitin chains. In the majority of tumors from patients with melanoma or colorectal cancer suffering from high rates of chemoresistance, NOXA fails to accumulate because UCH-L1 expression is epigenetically silenced. Whereas UCH-L1/NOXA-positive tumor samples exhibit increased sensitivity to genotoxic chemotherapy, downregulation of UCH-L1 or inhibition of its deubiquitylase activity resulted in reduced NOXA stability and resistance to genotoxic chemotherapy in both human and C. elegans cells. Our data identify the UCH-L1/NOXA interaction as a therapeutic target for overcoming cancer chemoresistance.
- Published
- 2013
- Full Text
- View/download PDF